Guardant Health, Inc. Price Chart
Guardant Health, Inc. 5GH.DE Financial and Trading Overview
| Guardant Health, Inc. stock price | 50.22 EUR |
| Previous Close | 50.22 EUR |
| Open | 50.22 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 50.22 - 50.22 EUR |
| 52 Week Range | 27.29 - 112.55 EUR |
| Volume | 300 EUR |
| Avg. Volume | 33 EUR |
| Market Cap | 5.32B EUR |
| Beta (5Y Monthly) | 0.799662 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.925 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
5GH.DE Valuation Measures
| Enterprise Value | 5.59B EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 11.024167 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 11.595 |
| Enterprise Value/EBITDA | -10.747 |
Trading Information
Guardant Health, Inc. Stock Price History
| Beta (5Y Monthly) | 0.799662 |
| 52-Week Change | -52.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 112.55 EUR |
| 52 Week Low | 27.29 EUR |
| 50-Day Moving Average | 43.15 EUR |
| 200-Day Moving Average | 60.53 EUR |
5GH.DE Share Statistics
| Avg. Volume (3 month) | 33 EUR |
| Avg. Daily Volume (10-Days) | 30 EUR |
| Shares Outstanding | 102.22M |
| Float | 98.39M |
| Short Ratio | N/A |
| % Held by Insiders | 4.65% |
| % Held by Institutions | 92.24% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -137.90% |
| Operating Margin (ttm) | -115.99% |
| Gross Margin | 63.20% |
| EBITDA Margin | -107.88% |
Management Effectiveness
| Return on Assets (ttm) | -19.19% |
| Return on Equity (ttm) | -272.22% |
Income Statement
| Revenue (ttm) | 482.15M EUR |
| Revenue Per Share (ttm) | 4.71 EUR |
| Quarterly Revenue Growth (yoy) | 33.90% |
| Gross Profit (ttm) | 293.21M EUR |
| EBITDA | -520179008 EUR |
| Net Income Avi to Common (ttm) | -664892992 EUR |
| Diluted EPS (ttm) | -3.925 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 937.02M EUR |
| Total Cash Per Share (mrq) | 9.12 EUR |
| Total Debt (mrq) | 1.37B EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.41 |
| Book Value Per Share (mrq) | -0.434 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -355284992 EUR |
| Levered Free Cash Flow (ttm) | -328236736 EUR |
Profile of Guardant Health, Inc.
| Country | Germany |
| State | CA |
| City | Palo Alto |
| Address | 3100 Hanover Street |
| ZIP | 94304 |
| Phone | 855 698 8887 |
| Website | https://guardanthealth.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 1793 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Q&A For Guardant Health, Inc. Stock
What is a current 5GH.DE stock price?
Guardant Health, Inc. 5GH.DE stock price today per share is 50.22 EUR.
How to purchase Guardant Health, Inc. stock?
You can buy 5GH.DE shares on the XETRA exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Guardant Health, Inc.?
The stock symbol or ticker of Guardant Health, Inc. is 5GH.DE.
How many shares does Guardant Health, Inc. have in circulation?
The max supply of Guardant Health, Inc. shares is 105.84M.
What is Guardant Health, Inc. Price to Earnings Ratio (PE Ratio)?
Guardant Health, Inc. PE Ratio is now.
What was Guardant Health, Inc. earnings per share over the trailing 12 months (TTM)?
Guardant Health, Inc. EPS is -3.925 EUR over the trailing 12 months.